Skip to Content
Interactive Textbook on Clinical Symptom Research Logo

Home Button

Hot Flashes Study Sections
 Author Bio
Introduction 
Commentator Bio
Protocol Schema
Protocol Background
Protocol Goals
Patient Eligibility
Test Schedule
Stratification Factors
Registration/Randomization
Currently selected section: Protocol Treatment
Dosage Modification
Ancillary Treatment
Toxicity Monitoring
Treatment Evaluation
Descriptive Factors
Treatment/Follow-up
Pharmacologic Studies
Drug Information
Statistical Considerations
Pathology Considerations
Records/Data Collection Procedures
Budget
Appendices

 

Chapter 2B: Development of a Clinical Trial for Hot Flash Protocol: Protocol Treatment
 

Microphone Image

7.1 Double-blind study

7.11 The patient will be instructed to avoid taking any study medication for the first seven days, but to complete their daily questionnaire during this baseline period. For the subsequent four weeks, patients will be instructed to take one tablet t.i.d. making sure to take medication from the correct week. Then they will start another four weeks of the alternative (blinded) product and complete four more weeks of questionnaires.

7.12 At study entry, the patient will be given the 10-page set of Daily Patient Questionnaires (Appendix III) to be filled out, and the procedure for completing each page of the set will be carefully explained.

7.121 The page labeled "First Study Week (Baseline)" should be filled out during the first seven days following study entry, to document the patient's baseline hot flashes. Patients should note Appendix IV outlines the definitions of mild, moderate, severe, very severe hot flashes.

7.122 The next page labeled "Second Study Week" should be filled out during the second seven days after study entry and so on for pages 3-9.

7.123 The 10th (and last) page labeled "Preference" should be filled out after the first nine weeks of study participation

7.13 Evaluation procedures

7.131 Each patient will be contacted by telephone week 2, start of week 5, week 7, and week 9 to document compliance, encourage completion of the questionnaires, and address problems. Phone calls may be omitted in those weeks in which the patient is seen at the NCCTG institution responsible for her primary care. However, the information obtained must be recorded on Appendix V.

7.132 Questionnaires should be returned to the investigator at the end of blinded treatment (i.e. after the 9th week following study entry). The patient should be supplied with an addressed/stamped envelope for returning the forms.

7.14 Emergency unblinding procedures

In the event of an emergency, call the Randomization Center at (555) 555-5555 to break the code on Monday through Friday, 8 a.m. to 4:30 p.m. central time. The Rochester Methodist Pharmacy will be available at any other time at (555) 555-5555. This is only in the event of an emergency. The pharmacy staff will require the study number and patient bottle number to break the code.


Page 13 of 29